These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 24372395)

  • 21. [The efficacy and safety of telbivudine in korean patients with chronic hepatitis B].
    Moon YM; Hwang SG; Kim BS; Rim KS; Cho M; Kim DJ; Han JY; Kim YS; Choi HS; Ahn SH
    Korean J Hepatol; 2007 Dec; 13(4):503-12. PubMed ID: 18159148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiviral therapy of chronic hepatitis B.
    van Bömmel F; Berg T
    Intervirology; 2014; 57(3-4):171-80. PubMed ID: 25034485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
    Coffin CS; Rezaeeaval M; Pang JX; Alcantara L; Klein P; Burak KW; Myers RP
    Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1262-9. PubMed ID: 25312649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection.
    Cho JH; Lim JH; Park GY; Kim JS; Kang YJ; Kwon O; Choi JY; Park SH; Kim YL; Kim HK; Huh S; Kim CD
    Transpl Infect Dis; 2014 Apr; 16(2):295-303. PubMed ID: 24628837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.
    Hou J; Yin YK; Xu D; Tan D; Niu J; Zhou X; Wang Y; Zhu L; He Y; Ren H; Wan M; Chen C; Wu S; Chen Y; Xu J; Wang Q; Wei L; Chao G; Constance BF; Harb G; Brown NA; Jia J
    Hepatology; 2008 Feb; 47(2):447-54. PubMed ID: 18080339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection.
    Kurokawa M; Hiramatsu N; Oze T; Yakushijin T; Miyazaki M; Hosui A; Miyagi T; Yoshida Y; Ishida H; Tatsumi T; Kiso S; Kanto T; Kasahara A; Iio S; Doi Y; Yamada A; Oshita M; Kaneko A; Mochizuki K; Hagiwara H; Mita E; Ito T; Inui Y; Katayama K; Yoshihara H; Imai Y; Hayashi E; Hayashi N; Takehara T
    J Gastroenterol; 2012 May; 47(5):577-85. PubMed ID: 22231575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long term nucleotide and nucleoside analogs treatment in chronic hepatitis B HBeAg negative genotype D patients and risk for hepatocellular carcinoma.
    Pellicelli AM; Vignally P; Messina V; Izzi A; Mazzoni E; Barlattani A; Bacca D; Romano M; Mecenate F; Stroffolini T; Furlan C; Picardi A; Gentilucci UV; Gulminetti R; Bonaventura ME; Villani R; D'Ambrosio C; Paffetti A; Mastropietro C; Marignani M; Fondacaro L; Cerasari G; Andreoli A; Barbarini G
    Ann Hepatol; 2014; 13(4):376-85. PubMed ID: 24927608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Telbivudine on IgG-associated hypergammaglobulinemia and TGF-β1 hyperactivity in hepatitis B virus-related liver cirrhosis.
    Ho CH; Chang TT; Chien RN
    PLoS One; 2019; 14(11):e0225482. PubMed ID: 31770396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-HBV drugs suppress the growth of HBV-related hepatoma cells via down-regulation of hepatitis B virus X protein.
    Zhang S; Gao S; Zhao M; Liu Y; Bu Y; Jiang Q; Zhao Q; Ye L; Zhang X
    Cancer Lett; 2017 Apr; 392():94-104. PubMed ID: 28192212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Telbivudine treatment corrects HBV-induced epigenetic alterations in liver cells of patients with chronic hepatitis B.
    Tian Y; Ni D; Yang W; Zhang Y; Zhao K; Song J; Mao Q; Tian Z; van Velkinburgh JC; Yang D; Wu Y; Ni B
    Carcinogenesis; 2014 Jan; 35(1):53-61. PubMed ID: 24067902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of sequential use of telbivudine in hepatitis B e antigen-positive chronic hepatitis B patients with partial responses to pegylated interferon: a pilot study.
    Huang Z; Zhao Z; Zheng Y; Peng L; Lin C; Deng H; Gao Z
    J Viral Hepat; 2013 Apr; 20 Suppl 1():52-7. PubMed ID: 23458525
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The degree of HBV suppression with 24 week telbivudine- or lamivudine-treatment in hepatitis B patients predicts the efficacy of the treatment at week 52].
    Jia JD; Hou JL; Yin YK; Xu DZ; Tan DM; Niu JQ; Zhou XQ; Wang YM; Zhu LM; He YW; Ren H; Wan MB; Chen CW; Wu SM; Chen YG; Xu JZ; Wang QH; Wei L; Ma H
    Zhonghua Gan Zang Bing Za Zhi; 2007 May; 15(5):342-5. PubMed ID: 17524265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [New insight for HBV DNA and HBsAg quantitation during antiviral therapy in patients with chronic hepatitis B].
    Cho YK; Song BC
    Korean J Gastroenterol; 2011 Mar; 57(3):144-9. PubMed ID: 21519161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine.
    Bowden S; Locarnini S; Chang TT; Chao YC; Han KH; Gish RG; de Man RA; Yu M; Llamoso C; Tang H
    World J Gastroenterol; 2015 Apr; 21(15):4644-51. PubMed ID: 25914474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients.
    Lin CC; Bair MJ; Chen CJ; Lee KH; Chen MJ; Liu CY; Chang CW; Hu KC; Liou TC; Lin SC; Wang HY; Chu CH; Shih SC; Wang TE
    Kaohsiung J Med Sci; 2016 Jan; 32(1):10-5. PubMed ID: 26853169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease.
    Eun JR; Lee HJ; Kim TN; Lee KS
    J Hepatol; 2010 Jul; 53(1):118-25. PubMed ID: 20471129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Telbivudine versus lamivudine in patients with chronic hepatitis B.
    Lai CL; Gane E; Liaw YF; Hsu CW; Thongsawat S; Wang Y; Chen Y; Heathcote EJ; Rasenack J; Bzowej N; Naoumov NV; Di Bisceglie AM; Zeuzem S; Moon YM; Goodman Z; Chao G; Constance BF; Brown NA;
    N Engl J Med; 2007 Dec; 357(25):2576-88. PubMed ID: 18094378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea.
    Park YH; Kim BK; Kim JK; Kim HC; Kim DY; Park JY; Han KH; Kim SU; Shin SH; Hahn KY; Ahn SH
    J Gastroenterol Hepatol; 2014 May; 29(5):1005-11. PubMed ID: 24325579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study.
    Chang Y; Choe WH; Sinn DH; Lee JH; Ahn SH; Lee H; Shim JJ; Jun DW; Park SY; Nam JY; Cho EJ; Yu SJ; Lee DH; Lee JM; Kim YJ; Kwon SY; Paik SW; Yoon JH
    J Infect Dis; 2017 Dec; 216(11):1407-1414. PubMed ID: 29029102
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of chronic hepatitis B: case selection and duration of therapy.
    Leung N
    J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.